PMID- 31378564
OWN - NLM
STAT- MEDLINE
DCOM- 20191125
LR  - 20191125
IS  - 1399-0020 (Electronic)
IS  - 0901-5027 (Linking)
VI  - 48
IP  - 12
DP  - 2019 Dec
TI  - Medication-related osteonecrosis of the jaw in a cancer patient receiving 
      lenvatinib.
PG  - 1530-1532
LID - S0901-5027(19)31239-1 [pii]
LID - 10.1016/j.ijom.2019.07.010 [doi]
AB  - Medication-related osteonecrosis of the jaw (MRONJ) is an adverse drug reaction 
      that affects the mandible and maxilla of patients exposed to bone-targeting 
      agents such as anti-resorptive and anti-angiogenic agents. Several MRONJ cases 
      have been reported after dental extractions in patients under treatment with 
      anti-angiogenic agents, including receptor activator of nuclear factor kappaB ligand 
      (RANKL) inhibitor, anti-vascular endothelial growth factor (anti-VEGF) monoclonal 
      antibody, mammalian target of rapamycin (mTOR) inhibitors, and tyrosine kinase 
      inhibitors (TKIs). The aim of this article was to describe an original case of 
      lenvatinib-related osteonecrosis of the jaw in a patient affected by thyroid 
      cancer. A 58-year-old man diagnosed with Hurthle cell thyroid cancer, who was 
      undergoing treatment with lenvatinib, developed maxillary osteonecrosis after a 
      dental extraction. No other concomitant local or systemic risk factors for MRONJ 
      were present. With new cancer therapies applied every year, it is important to 
      note this novel case of lenvatinib osteonecrosis of the jaw in a patient 
      undergoing cancer treatment.
CI  - Copyright (c) 2019 The Authors. Published by Elsevier Ltd.. All rights reserved.
FAU - Mauceri, R
AU  - Mauceri R
AD  - Department of Surgical, Oncological, and Oral Sciences, Sector of Oral Medicine 
      "Valerio Margiotta", University of Palermo, Palermo, Italy.
FAU - Panzarella, V
AU  - Panzarella V
AD  - Department of Surgical, Oncological, and Oral Sciences, Sector of Oral Medicine 
      "Valerio Margiotta", University of Palermo, Palermo, Italy.
FAU - Morreale, I
AU  - Morreale I
AD  - Clinical Pharmacology Unit, Sicilian Regional Centre of Pharmacovigilance, 
      Azienda Ospedaliera Universitaria Policlinico P. Giaccone, University of Palermo, 
      Palermo, Italy.
FAU - Campisi, G
AU  - Campisi G
AD  - Department of Surgical, Oncological, and Oral Sciences, Sector of Oral Medicine 
      "Valerio Margiotta", University of Palermo, Palermo, Italy. Electronic address: 
      campisi@odonto.unipa.it.
LA  - eng
PT  - Journal Article
DEP - 20190802
PL  - Denmark
TA  - Int J Oral Maxillofac Surg
JT  - International journal of oral and maxillofacial surgery
JID - 8605826
RN  - 0 (Bone Density Conservation Agents)
RN  - 0 (Diphosphonates)
RN  - 0 (Phenylurea Compounds)
RN  - 0 (Quinolines)
RN  - EE083865G2 (lenvatinib)
SB  - IM
MH  - Animals
MH  - *Bisphosphonate-Associated Osteonecrosis of the Jaw
MH  - *Bone Density Conservation Agents
MH  - Diphosphonates
MH  - Humans
MH  - Male
MH  - Middle Aged
MH  - *Osteonecrosis
MH  - Phenylurea Compounds
MH  - *Quinolines
OTO - NOTNLM
OT  - MRONJ
OT  - dental extraction
OT  - lenvatinib
OT  - osteonecrosis of the jaw
EDAT- 2019/08/06 06:00
MHDA- 2019/11/26 06:00
CRDT- 2019/08/06 06:00
PHST- 2018/12/02 00:00 [received]
PHST- 2019/05/17 00:00 [revised]
PHST- 2019/07/15 00:00 [accepted]
PHST- 2019/08/06 06:00 [pubmed]
PHST- 2019/11/26 06:00 [medline]
PHST- 2019/08/06 06:00 [entrez]
AID - S0901-5027(19)31239-1 [pii]
AID - 10.1016/j.ijom.2019.07.010 [doi]
PST - ppublish
SO  - Int J Oral Maxillofac Surg. 2019 Dec;48(12):1530-1532. doi: 
      10.1016/j.ijom.2019.07.010. Epub 2019 Aug 2.